Table 2.
Effects of the Src inhibitor, dasatinib, on the cell cycle
| Vehicle (control)
|
Dasatinib, 10 nmol/L
|
Dasatinib, 50 nmol/L
|
|||||||
|---|---|---|---|---|---|---|---|---|---|
| G1 | S | G2–M | G1 | S | G2–M | G1 | S | G2–M | |
| BCPAP | 64.8 | 26.5 | 8.7 | 73.4 | 18.5 | 8.1 | 87.2 | 9.3 | 3.4 |
| SW1736 | 77.5 | 16.9 | 5.6 | 86.0 | 10.2 | 3.7 | 88.5 | 6.9 | 4.6 |
| K1 | 70.7 | 21.1 | 8.2 | 79.7 | 14.5 | 5.8 | 87.4 | 10.2 | 2.4 |
| 8505C | 58.6 | 28.9 | 12.5 | 58.5 | 30.1 | 11.4 | 65.5 | 23.1 | 11.4 |
| HTh7 | 61.1 | 26.8 | 12.2 | 60.8 | 27.0 | 12.2 | 67.2 | 23.9 | 8.9 |
| HTh74 | 65.3 | 22.5 | 12.2 | 71.1 | 19.0 | 9.9 | 75.1 | 17.3 | 7.6 |
NOTE: Cells were treated with the indicated dose of dasatinib or vehicle for 48 hours. Cell-cycle distribution was determined using the PI/saponin method. Results are the mean of 2 to 4 experiments.